HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 21, No 04, April 2017 – Diabetes: The Big Picture       » ASEAN+ Rare Disease Network Established       » New Superbug Could Be Epidemic       » China Building World's Largest Multifunctional Nano Research Facility       » NUS Study: Daily Consumption of Tea Protects the Elderly from Cognitive Decline       » Diabetes in Your DNA?       » Wearable Biosensors Can Tell You When to See the Doctor      
BIOBOARD - INSIDE INDUSTRY
Biametrics successfully finalizes feasibility study with MorphoSys in the area of high-throughput antibody screening
Biametrics GmbH and MorphoSys AG plan to further collaborate in the area of high-throughput antibody screening.

Biametrics performed a very successful screening study using MorphoSys' reagents and Biametrics' label-free microarray based instrumentation b-screen for the characterization of Fab fragment antigen interactions. The feasibility study clearly demonstrated the advantages of b-screen to speed up the overall antibody screening process using the microarray format. Recently, Biametrics launched their b-screen device for high-throughput biomolecular interaction screening/analysis.

"We are delighted to be collaborating with MorphoSys, a leader in the development of biotherapeutics," said Dr. Florian Pröll, Managing Director of Biametrics "We look forward to expand our collaboration in the field of biomolecular interaction analysis."

Biametrics' b-screen device enables the detection of these biomolecules in a high-density array format on microscope slide disposables. Thereby, no fluorescence labels are needed for read-out. This leads to minimized sample pre-treatment and reagent consumption. With this new optical detection method, it is possible to reduce the complexity of the conventional label-free assays while enhancing the throughput and maintaining precision and reliability.

"We have identified b-screen as an promising technology in the field of epitope mapping, and will now broaden our collaboration with Biametrics", added Dr. Markus Enzelberger, Senior VP, Head of Discovery Alliances & Technologies at MorphoSys AG.

The collaboration between MorphoSys AG as a globally established supplier of therapeutic antibodies and Biametrics as an aspiring technology company allows for a fast and successful development of such biopharmaceuticals. MorphoSys will continue the cooperation with Biametrics.

Source: B3C Newswire

Click here for the complete issue.

NEWS CRUNCH  
news Healthcare Sustainability in Asia: Now is the Time to Act — FT Asia Healthcare & Life Sciences Summit 2017
news Philip Morris International and British American Tobacco receive award from PETA science group for AOP developments
news 6th Asia-Pacific Breast Cancer Summit to take place in Hong Kong
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2017
January:
Healthcare Focus: LUNGS
February:
War on CANCER
March:
Get to Know TCM
April:
Diabetes: The Big Picture
May:
The Piece of Your Mind - Brain Health/Science
June:
Rare Diseases
July:
Food Science & Technology
August:
Eye Care/ Eye Health
September:
No. 1 Killer - Heart Diseases, Diagnosis and Treatment
October:
Skin Diseases/Allergic Reactions
November:
Diseases threatening our Children
December:
Liver Health & Treatment/Technology
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2017 World Scientific Publishing Co Pte Ltd  •  Privacy Policy